Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data on September 26, 2011, from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands. The two podium presentations review the results from the Company's two clinical trials of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis (BE) patients.

The Phase 2b study ORBIT-2 (Once-Daily Respiratory Bronchiectasis Inhalation Treatment) was a 168 day, double-blind, placebo-controlled trial in 42 randomized BE patients with once daily ARD-3150 (Pulmaquin™) that resulted in excellent reduction of Pseudomonas aeruginosa colony forming units (CFUs), as well as a significant increase in the time to first exacerbation in the active group vs. placebo. Most recently, the Company reported positive top line data from the Phase 2b study ORBIT-1 with Aradigm's ciprofloxacin for inhalation (ARD-3100, Lipoquin™) in patients with non-cystic fibrosis bronchiectasis. The primary endpoint - the mean change in Pseudomonas aeruginosa CFUs from baseline to day 28 - was met in the full analysis population with both the 2 mL and 3 mL doses vs. placebo.